Given that IL-1 is implicated in the pathogenesis of AOSD [115–116] and its ligands and receptors are secreted mainly by activated macrophages, the administration of IL-1-blocking agents in AOSD patients seems to be a logical therapeutic approach with a corticosteroid-sparing effect [24–25, 117–120]. The gene discussed is IL1A; the disease is adult-onset Still disease.